PMID: 8611476Apr 1, 1996Paper

Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia

British Journal of Haematology
J E AndersonR Storb

Abstract

Allogeneic marrow transplantation using related marrow donors for myelodysplasia (MDS) and acute myeloid leukaemia (AML) arising from MDS results in 35-56% actuarial disease-free survival. Because the use of unrelated donors has not been well-characterized, we report on the outcome of 52 patients with MDS or MDS-related AML consecutively treated between 1987 and 1993 with unrelated donor marrow transplantation. The median age was 33 (range 1-53) years. 33 patients received chemotherapy and total body irradiation and the remainder busulfan and cyclophosphamide. The donors were phenotypically identical at the HLA-A, B and Dw/DRB1 loci in 34 cases and mismatched for one HLA locus in 17 cases and two loci in one case. Marrow was non-T-cell depleted and methotrexate with cyclosporine or FK506 was used for postgrafting immunosuppression. The 2-year disease-free survival, relapse, and non-relapse mortality rates were 38%, 28% and 48%, respectively. One patient who relapsed survives disease-free after withdrawal of immunosuppressive therapy. 16/19 survivors have a performance status of 90-100%. Patients with MDS in transformation or with AML had a significantly higher risk of relapse than patients with less advanced disease (P = 0.0014...Continue Reading

Citations

Nov 26, 1999·Cancer·H D Preisler
Oct 21, 2004·Best Practice & Research. Clinical Haematology·John McCarty
Sep 12, 1998·Leukemia Research·F R Appelbaum, J Anderson
Dec 12, 2001·Critical Reviews in Oncology/hematology·F D Pisani, A Rainaldi
Jul 24, 2012·Leukemia·N KrögerUNKNOWN MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
May 26, 1999·The New England Journal of Medicine·M L Heaney, D W Golde
Feb 25, 2000·Current Opinion in Oncology·R Dansey
Apr 6, 2000·Current Opinion in Oncology·C AnasettiJ A Hansen
Oct 18, 2001·Current Opinion in Hematology·C AnasettiJ A Hansen
Jan 21, 2006·AJR. American Journal of Roentgenology·Evguenia J KarimovaSue C Kaste
Apr 23, 2011·AJR. American Journal of Roentgenology·Sue C KasteMichael D Neel
Jan 1, 2009·F1000 Medicine Reports·Yi-Bin Chen, Karen K Ballen
Apr 19, 2000·Lancet·D Provan, D Weatherall
Sep 19, 2003·Wiener klinische Wochenschrift·Peter ValentKlaus Geissler
May 30, 2001·Leukemia & Lymphoma·G LeoneL Pagano
Feb 5, 2008·Pediatric Clinics of North America·Rupert HandgretingerR Maarten Egeler
Jan 9, 2008·Seminars in Hematology·A John Barrett, Bipin N Savani
Oct 16, 2015·Hematology/oncology and Stem Cell Therapy·Edward A CopelanBelinda R Avalos
Jan 1, 2014·British Journal of Haematology·Sally B KillickUNKNOWN British Committee for Standards in Haematology
Apr 2, 2002·Best Practice & Research. Clinical Haematology·D I Marks
Jun 9, 2006·Blood Reviews·Wendy IngramGhulam J Mufti
Jun 20, 2006·Best Practice & Research. Clinical Haematology·Bart Scott, H Joachim Deeg
May 5, 2004·Seminars in Oncology·Amelia A LangstonElliott F Winton
Nov 30, 1999·Hematology/oncology Clinics of North America·L Popplewell, S J Forman
Jan 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul SzabolcsAngus W Thomson
Jul 29, 2000·Blood Reviews·J E Anderson
Feb 11, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stella M DaviesNancy A Kernan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.